BDBM246875 4-(4-{3- [(dimethylamino) methyl]-5- fluorophenoxy} piperidin-1-yl)-3- [4-(7H- pyrrolo[2,3- d]pyrimidin-4-yl)- 1H-pyrazol-1- yl]butanenitrile::BDBM596391::US10053465, 14::US10065963, Compound 14::US10125150, Example 14::US10336759, # 14::US10479803, Example 14::US10675284, Example 14::US11084822, Example 14::US11130767, # 14::US11136326, Example 14::US11304949, Compound 14::US11324749, Comp. No. 14::US11406640, Comp. No. 14::US11918581, Compound 14::US11957661, Compound 14::US11992490, Compound 14::US12226418, Example 14::US20240058343, Compound 14::US20240307353, Compound 14::US9732097, Example 14
SMILES CN(C)Cc1cc(F)cc(OC2CCN(CC(CC#N)n3cc(cn3)-c3ncnc4[nH]ccc34)CC2)c1
InChI Key InChIKey=CEIFLXZQZIUBTK-UHFFFAOYSA-N
Data 22 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 22 hits for monomerid = 246875
Affinity DataIC50: 10nMAssay Description:The IC50s obtained by the method of Assay A at 1 mM ATP as described in the US Patent Publications.More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+3nMAssay Description:The catalytic activity of JAK1, JAK2 or JAK3 was assayed by measuring the phosphorylation of a biotinylated peptide. The phosphorylated peptide was d...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:JAK1 inhibitors that can be used for the treatment of cytokine-related diseases or disorders are tested for inhibitory activity of JAK targets accord...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Selective JAK1 inhibitors that can be used in combination with a ROCK inhibitor as described herein are tested for inhibitory activity of JAK targets...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:JAK1 pathway inhibitors that can be used for the treatment of cytokine-related diseases or disorders were tested for inhibitory activity of JAK targe...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:JAK1 pathway inhibitors that can be used for the treatment of cytokine-related diseases or disorders were tested for inhibitory activity of JAK targe...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:JAK1 inhibitors that can be used for the treatment of cytokine-related diseases or disorders are tested for inhibitory activity of JAK targets accord...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:JAK1 pathway inhibitors that can be used for the treatment of cytokine-related diseases or disorders are tested for inhibitory activity of JAK target...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Selective JAK1 inhibitors that can be used in combination with an immunomodulatory agent and steroid for the treatment of hematological diseases or d...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:JAK1 pathway inhibitors that can be used for the treatment of cytokine-related diseases or disorders are tested for inhibitory activity of JAK target...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:JAK1 inhibitors that can be used for the treatment of cytokine-related diseases or disorders are tested for inhibitory activity of JAK targets accord...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:The compounds in Table A were tested for inhibitory activity of JAK targets according to the following in vitro assay described in Park et al., Analy...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:The compounds in Table 1 were tested for inhibitory activity of JAK targets according to the following in vitro assay described in Park et al., Analy...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Assays are carried out at room temperature in 50 mM HEPES, pH 7.4, 5 mM MgCl2, 50 mM NaCl, 5 mM DTT and CHAPS 0.04%. Reactions are initiated by the a...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:JAK1 pathway inhibitors that can be used for the treatment of cytokine-related diseases or disorders are tested for inhibitory activity of JAK target...More data for this Ligand-Target Pair
Affinity DataIC50: 50nMAssay Description:Compounds herein were tested for inhibitory activity of JAK targets according to the following in vitro assay described in Park et al., Analytical Bi...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:PI3K: The kinase reactions are conducted in clear-bottom 96-well plate from Thermo Fisher Scientific in a final volume of 24 μL. Inhibitors are ...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:PI3-Kinase luminescent assay kit including lipid kinase substrate, D-myo-phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2)D (+)-sn-1,2-di-O-octan...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:The kinase reaction was conducted in clear-bottom 96-well plate from Thermo Fisher Scientific in a final volume of 24 μL. Inhibitors were first ...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:As used herein, a selective JAK1 inhibitor is an inhibitor of JAK1 which is selective for JAK1 over JAK2, JAK3 and TYK2. In some embodiments, the com...More data for this Ligand-Target Pair
Affinity DataIC50: 100nMpH: 7.8 T: 2°CAssay Description:Compounds herein were tested for inhibitory activity of JAK targets according to the following in vitro assay described in Park et al., Analytical Bi...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a met...More data for this Ligand-Target Pair